FierceBiotech Mar 12, 2026 Ultragenyx gene therapy hits co-primary endpoint in phase 3 rare disease study, teeing up potential win
FierceBiotech Mar 12, 2026 Regenxbio posts clean safety profile for DMD gene therapy as pivotal data loom
FierceBiotech Mar 12, 2026 Novo Holdings sees assets shrink by a 3rd in wake of Novo Nordisk's nosediving share price
FierceBiotech Mar 11, 2026 How a new tool for large-scale gene editing could power novel genetic medicines
FierceBiotech Mar 11, 2026 Evotec reveals sweeping 800-person layoffs, more site closures as restructuring rolls on
FierceBiotech Mar 11, 2026 CNS Pharma wipes glioblastoma pipeline clean in strategic pivot to fresh neurology, oncology targets
FierceBiotech Mar 11, 2026 Despite delays, NIH grants generated a 250% return on $36.6B investment in 2025: report
FierceBiotech Mar 11, 2026 Salspera plans $91M IPO to fund phase 3 studies of salmonella-based cancer therapy
FierceBiotech Mar 10, 2026 Lilly pledges $500M to South Korea biopharma industry, following Roche’s lead
FierceBiotech Mar 10, 2026 Molecular glue biotech shutters after ‘brutal’ few years for early-stage companies
FierceBiotech Mar 10, 2026 FDA approves leucovorin for ultrarare cerebral folate deficiency subset without clinical trial